Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by Walterthedogon Jul 08, 2021 10:44am
159 Views
Post# 33511783

RE:RE:RE:News and update

RE:RE:RE:News and update And to top it off, if we do beat Aspire in court and they are legally compelled to hand over whatever info they have, whos to say they dont alter it to show no efficacy as they and Accudata claimed it to have shown over a year ago? If it clearly showed efficacy and they claimed it didn't, that would be something they would want to cover up. Hopefully Medrio has all that info and there aren't portions that Aspire exclusively holds. The florida court case has a recent letter from Medrio explaining that they basically aren't handing over anything to either party until clear title to the assets is determined. All i know is that if this trial data is lost in this court battle and they have to start from scratch, it will be a very difficult thing to raise all that money again, especially since all the shenanigans that took place around this current mess. I hope to Christ that I'm wrong and that hemostemix can somehow rebuild the trial from site visits but i really feel that without Aspires co-operation and some kind if agreement, that this simply won't be possible. The NR just stated that Aspire is witholding batch info? Seems like critical info that you can't get from blinded clinical trial workers.
<< Previous
Bullboard Posts
Next >>